Combination Immunotherapy For The Treatment of Cancer

Abstract

Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

1 . A method of treating cancer in a patient comprising administering to the patient a blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody and an agonist anti-ICOS antibody. 
     
     
         2 . The method of  claim 1 , wherein the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody and the agonist anti-ICOS antibody are administered simultaneously or sequentially. 
     
     
         3 . The method of  claim 1 , wherein the agonist anti-ICOS antibody is a monoclonal antibody. 
     
     
         4 . The method of  claim 3 , wherein the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody is a monoclonal antibody. 
     
     
         5 . The method of  claim 4 , wherein the agonist anti-ICOS antibody is a humanized antibody. 
     
     
         6 . The method of  claim 3 , wherein the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody is a humanized antibody. 
     
     
         7 . The method of  claim 1 , wherein the agonist anti-ICOS antibody is a humanized antibody. 
     
     
         8 . The method of  claim 7 , wherein the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody is a humanized antibody. 
     
     
         9 . The method of  claim 1 , consisting of administering to the patient one or more doses of the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody and one or more doses of the agonist anti-ICOS antibody. 
     
     
         10 . The method of  claim 9 , wherein at least one dose of the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody and at least one dose of the agonist anti-ICOS antibody are administered simultaneously or sequentially. 
     
     
         11 . The method of  claim 9 , wherein the agonist anti-ICOS antibody is a monoclonal antibody. 
     
     
         12 . The method of  claim 11 , wherein the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody is a monoclonal antibody. 
     
     
         13 . The method of  claim 12 , wherein the agonist anti-ICOS antibody is a humanized antibody. 
     
     
         14 . The method of  claim 11 , wherein the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody is a humanized antibody. 
     
     
         15 . The method of  claim 9 , wherein the agonist anti-ICOS antibody is a humanized antibody. 
     
     
         16 . The method of  claim 15 , wherein the blocking antibody selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody and a blocking anti-PD-L1 antibody is a humanized antibody. 
     
     
         17 . The method of  claim 4 , wherein the method does not comprise administering another antitumor treatment. 
     
     
         18 . The method of  claim 4 , wherein the method does not comprise administering another antitumor treatment other than surgical resection or radiation therapy. 
     
     
         19 . The method of  claim 4 , wherein the method does not comprise administering another immunotherapy.